Answers are grounded in this paper and cite their sources.
The FDA has approved a third ALK inhibitor, alectinib, for advanced ALK-positive non–small cell lung cancer. Two phase II studies show that patients who have become resistant to crizotinib respond well to alectinib; the drug is also effective against brain metastases, which are common in this disease subtype.
No takes yet. Share an insight, caveat, or question.
A 2016 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: